Current Report Filing (8-k)
September 07 2021 - 4:17PM
Edgar (US Regulatory)
0001711754
false
0001711754
2021-09-07
2021-09-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 7, 2021
|
INMUNE
BIO INC.
|
|
|
(Exact name of registrant
as specified in charter)
|
|
Nevada
|
|
001-38793
|
|
47-5205835
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
980
North Federal Highway, Suite 110
Boca
Raton, Florida 33432
(Address
of Principal Executive Offices) (Zip Code)
(858)
964 3720
(Registrant’s
Telephone Number, Including Area Code)
Not
Applicable
(Former
Name or Former Address, If Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per shares
|
|
INMB
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other
Events.
The
Company is filing as Exhibit 99.1 to this Current Report on Form 8-K a slide deck that the Company intends to use in a presentation.
The Company is also filing as Exhibit 99.2 a presentation that it intends to use in a Webinar. By filing this Current Report on Form
8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this
report that is required to be disclosed solely by reason of Regulation FD.
The
information contained in the Presentations is summary information that is intended to be considered in the context of the Company's Securities
and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise,
from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in
this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made
through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.
Item 9.01
Financial statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
INMUNE BIO
INC.
|
|
|
Date: September
7, 2021
|
By:
|
/s/
David Moss
|
|
|
David Moss
|
|
|
Chief Financial Officer
|
2
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Aug 2024 to Sep 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Sep 2023 to Sep 2024